Journal of Clinical Oncology
Articles in this Issue
Sociodemographic disparities in treatment (tx) patterns and clinical outcomes among real-world patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) in the US.
707 Background: Sociodemographic disparities in la/mUC pt population include worse survival outcomes observed among certain pt subgroups. This study evalu...
Evaluation of de novo oligometastatic prostate cancer patients managed with radiation therapy: A multi-institution, real-world dataset.
113 Background: Oligometastatic prostate cancer (omPCa) is an understudied entity, historically defined as ≤5 non-visceral metastases. However, its true p...
Efficacy of targeted therapies (TT) after HIF-2⍺ inhibitor-based treatment in advanced renal cell carcinoma (aRCC).
508 Background: Hypoxia-inducible factor 2⍺ (HIF) inhibitors are active in renal cell carcinoma refractory to prior treatment with tyrosine kinase inhibit...
Real-world analysis of the efficacy and safety of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma: A multicenter retrospective study.
712 Background: We investigated the efficacy and safety enfortumab vedotin (EV) in patients with locally advanced or metastatic urothelial carcinoma in re...
Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.
459 Background: The TiNivo-2 study assessed TIVO 0.89 mg + NIVO vs TIVO 1.34 mg in patients with RCC that progressed after ICI therapy. This study did not...
Global, phase 3, open-label, single arm studies to evaluate the efficacy, safety, and pharmacokinetics of FP-014, 11.25 mg (triptorelin mesylate injection, 11.25 mg) and FP-014, 22.5 mg (triptorelin mesylate injection, 22.5 mg) in patients with advanced prostate cancer.
TPS284 Background: When given continuously, long-acting LH-RH agonist triptorelin is known to inhibit pituitary gonadotropin secretion and suppress testic...
Prostate cancer liver metastases: Genomic profiling and clinical outcomes.
189 Background: Patients (pts) with metastatic prostate cancer and liver metastases have poor prognosis, but clinicogenomic analyses are limited. We exami...
The prognostic value of LDH in patients with good risk metastatic seminoma treated with single agent carboplatin AUC10.
644 Background: Raised lactate dehydrogenase (LDH) is a surrogate marker for disease burden and an independent adverse prognostic factor for IGCCCG good r...
Efficacy and safety of lenvatinib plus everolimus in metastatic renal cell carcinoma after immune checkpoint and VEGFR tyrosine kinase inhibitors.
489 Background: Limited studies have investigated the real-world effectiveness and safety of Lenvatinib (LEN) combined with everolimus (EVE) in metastatic...
How unfavorable is AUA unfavorable intermediate-risk prostate cancer? Results from a large, institutional cohort.
342 Background: Major clinical guidelines including the American Urology Association (AUA) defines unfavorable intermediate-risk prostate cancer (UIR-PCa)...
CTC and AR-V7 analysis in the ECOG-ACRIN 8153 (CHAARTED2) randomized trial: Abiraterone (Abi) with or without cabazitaxel (Abi-Cabazi) in extensive mCRPC following docetaxel.
181 Background: The CHAARTED2 trial showed improved PFS with Abi-Cabazi over Abi-alone in patients (pts) with metastatic castration-resistant prostate can...
In-field progression following radiation therapy as a prognostic biomarker for lutetium-177-PSMA-617 response in metastatic castration-resistant prostate cancer.
86 Background: Prostate cancer often expresses prostate-specific membrane antigen (PSMA), which serves as a diagnostic and therapeutic target. Lutetium-17...
Olanzapine for managing side effects from tyrosine-kinase inhibitors.
524 Background: Antiangiogenic tyrosine kinase inhibitors (TKIs) play a key role in treating renal cell carcinoma and other solid organ malignancies, but...
Impact of variant allele frequency (VAF) of <i>TP53</i> alterations and Signatera circulating tumor DNA (ctDNA) monitoring for patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV).
830 Background: EV is now a standard of care for pts with aUC, both as monotherapy and with pembrolizumab (EVP). Factors predictive of primary refractory...
Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).
TPS298 Background: The backbone of prostate cancer systemic treatment is androgen deprivation therapy (ADT) increasingly with the use of androgen receptor...
Impact of homologous recombination repair alterations ( <i>HRRalt</i> ) on survival outcomes of patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
205 Background: Up to 30% of pts with advanced prostate cancer have HRRalt [PMID: 32343890]. The presence of tumor HRR...
Temporal trends and socioeconomic determinants of cytoreductive nephrectomy (CN) utilization for metastatic renal cell carcinoma (mRCC) in the United States (US).
447 Background: The evolving treatment landscape in mRCC since the advent of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has...
Image-based artificial intelligence algorithms for molecular diagnostics in prostate pathology: How far are we? A systematic review.
193 Background: Guidelines recommend molecular diagnostics for homologous and mismatch repair (MMR) defects in men with metastatic castration-resistant pr...
Time to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial.
173 Background: It is well-established that pts with de-novo mHSPC have poorer survival compared to those with metachronous disease. However, the impact o...
Circulating tumor DNA (ctDNA) monitoring in the assessment and prediction of the efficacy of PARP inhibitors (PARPi).
TPS307 Background: PARP inhibitors (PARPi) emerged as an promising treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with BRC...
<i>MTAP</i> loss in primary kidney tumors: A comprehensive genomic profiling study.
564 Background: Kidney tumors (KT) comprises approximately 4% of all new cancer cases in US per year, with about a third being de-novo...
Development of an miRNA signature for individual prognostic assessment in seminoma patients.
645 Background: Due to the risk of long-term toxicities in young non-metastatic seminoma patients, surveillance regimens nowadays are the standard of care...
Variants of unknown significance (VUS) in DNA repair genes in Caucasian men with muscle invasive bladder cancer (MIBC): A case of “serendipity” pushing for a BC screening program.
683 Background: In 2021 we started an enhanced PCa screening in healthy Caucasian men with germline DNA repair pathogenic variants. Over 109 enrolled men,...
Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.
661 Background: Most patients following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) face a poor prognosis. Combination of...
T suppression and recovery with AAP after early discontinuation of LHRH-A in high-risk localized (HRL), lymph node-positive (N+), or oligometastatic (OM) prostate cancer (PC).
55 Background: Intensified androgen deprivation therapy (iADT) with the addition of abiraterone acetate + prednisone (AAP) to a luteinizing hormone releas...